Ralf Clemens Selected Research

Inactivated Poliovirus Vaccine (Salk Vaccine)

1/2021	Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials.
9/2017	The Immunogenicity of Fractional Intradermal Doses of the Inactivated Poliovirus Vaccine Is Associated With the Size of the Intradermal Fluid Bleb.
1/2017	Inactivated polio vaccines from three different manufacturers have equivalent safety and immunogenicity when given as 1 or 2 additional doses after bivalent OPV: Results from a randomized controlled trial in Latin America.
7/2016	Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial.
1/2016	Safety and immunogenicity of inactivated poliovirus vaccine when given with measles-rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non-inferiority trial in The Gambia.
11/2015	Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ralf Clemens Research Topics

Disease

12	Poliomyelitis (Polio) 01/2021 - 05/2007
6	Human Influenza (Influenza) 01/2015 - 10/2010
5	Pain (Aches) 01/2022 - 01/2011
5	COVID-19 01/2022 - 01/2021
4	Infections 01/2022 - 08/2007
3	Gastroenteritis 03/2015 - 01/2006
2	Intussusception 11/2015 - 01/2006
2	Hemolysis 07/2012 - 10/2010
2	Hepatitis B 06/2009 - 05/2007
1	Reinfection 01/2022
1	Hypersensitivity (Allergy) 01/2021
1	Blister (Bulla) 09/2017
1	Measles 01/2016
1	Yellow Fever 01/2016
1	Rubella (German Measles) 01/2016
1	Diarrhea 03/2015
1	Vomiting 03/2015
1	Fever (Fevers) 12/2014
1	Narcolepsy 09/2011
1	Cataplexy 09/2011
1	Whooping Cough (Pertussis) 05/2007
1	Tetanus 05/2007
1	Diphtheria 05/2007
1	Falciparum Malaria (Plasmodium falciparum Malaria) 04/2004

Drug/Important Bio-Agent (IBA)

28	VaccinesIBA 01/2022 - 01/2006
6	Inactivated Poliovirus Vaccine (Salk Vaccine)FDA Link 01/2021 - 11/2015
6	Influenza Vaccines (Influenza Vaccine)FDA Link 01/2015 - 06/2011
5	Oral Poliovirus Vaccine (Sabin Vaccine)IBA 01/2021 - 11/2015
4	SCB-2019 COVID-19 vaccineIBA 01/2022 - 01/2021
2	AntibodiesIBA 01/2022 - 10/2018
2	COVID-19 VaccinesIBA 01/2022 - 01/2022
2	aluminum sulfate (alum)IBA 01/2022 - 01/2021
2	Neutralizing AntibodiesIBA 01/2021 - 12/2017
2	MF59 oil emulsionIBA 10/2011 - 09/2011
2	EmulsionsIBA 10/2011 - 09/2011
2	AntigensIBA 10/2010 - 05/2007
1	Recombinant ProteinsIBA 01/2022
1	sinovac COVID-19 vaccineIBA 01/2022
1	Protein SIBA 11/2021
1	AS03 adjuvantIBA 01/2021
1	Poliovirus VaccinesIBA 01/2021
1	Protein Subunits (Protein Subunit)IBA 01/2021
1	Combined VaccinesIBA 01/2016
1	Yellow Fever Vaccine (Vaccine, Yellow Fever)FDA Link 01/2016
1	4CMenB vaccineIBA 02/2012
1	polyribitol phosphateIBA 06/2009
1	Hepatitis B Core AntigensIBA 08/2007
1	Immunoglobulin M (IgM)IBA 08/2007
1	Hepatitis B Surface Antigens (HBsAg)FDA Link 08/2007
1	Attenuated VaccinesIBA 01/2006
1	Primaquine FDA Link 04/2004
1	Quinine (Quinson)FDA Link 04/2004
1	ArtesunateIBA 04/2004

Therapy/Procedure

1	Injections 06/2011